
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
<>
Julian Upton serves as European Editor for Pharm Exec and as Editor of its digital sister publication, Pharm Exec Global Digest. Julian first joined Advanstar Communications in 1998 and has worked in various editorial capacities for the company. Outside Advanstar, he has edited business magazines on topics ranging from healthcare to finance and defence.






